Health Minister Linas Kukuraitis stated that recent adjustments are significant for thousands of patients. He emphasized that the expanded coverage of the treatment options will provide both patients and doctors with more choices, particularly in situations where prior treatments were ineffective or if the disease has recurred. Specifically, support treatment involving Rukaparib, a medication designed to slow the growth of tumors, will now be covered for adult patients diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Furthermore, this coverage extends to women who have achieved either a complete or partial response following chemotherapy. In addition to these changes, the list of covered medicines has been broadened to include Dostramin. This addition represents an immunotherapy drug that assists the human immune system in recognizing and destroying cancer cells.
These updates are intended to enhance the available treatment protocols, offering patients and medical professionals more comprehensive options for managing various forms of cancer. The goal of these policy changes is to ensure that patients have access to the latest advancements in cancer care.
Topics: #patients #treatment #more
